
Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population
Newly presented data from the phase 4 CHIMES study (NCT04377555) revealed that treatment with ocrelizumab (Ocrevus; Genentech) has therapeutically beneficial impacts on perceived symptoms, cognition, and fatigue among Black and Hispanic/Latino patients …